Company

Tricida, Inc.

Tricida, Inc. is a biopharmaceutical company developing therapies for kidney disorders in chronic kidney disease.

About

Founded in 2013 and headquartered in San Francisco, US, Tricida, Inc. develops therapies for kidney disorders, with a lead candidate aimed at metabolic acidosis in chronic kidney disease patients. CEO Gerrit Klaerner leads the company. Its most recent funding round was a USD 25.00 mn VENTURE DEBT round supported by Hercules Capital on June 27, 2018. The company has raised a total of USD 42.00 mn, and its June 2018 IPO on NASDAQ raised USD 222.30 mn from selling shares.

7Funding rounds

11Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in